Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
- First Posted Date
- 2007-03-19
- Last Posted Date
- 2019-11-22
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 286
- Registration Number
- NCT00448539
- Locations
- ๐บ๐ธ
Comprehensive Epilepsy Care Center for Children and Adults, Chesterfield, Missouri, United States
๐บ๐ธChild Neurology Associates, PC, Atlanta, Georgia, United States
๐บ๐ธJohn Hopkins Hospital, Dept. of Neurology, Baltimore, Maryland, United States
Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism
- Conditions
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT00442234
Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
- Conditions
- Interventions
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT00441090
- Locations
- ๐บ๐ธ
Johns Hopkins University, Baltimore, Maryland, United States
๐บ๐ธUniversity of California Irvine Cancer Center, Orange, California, United States
๐บ๐ธFlorida Cancer Institute, New Port Richey, Florida, United States
A Study of E2007 In Patients With Parkinson's Disease
- First Posted Date
- 2007-01-26
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT00427011
- Locations
- ๐บ๐ธ
Brain Matters Research, Delray Beach, Florida, United States
๐บ๐ธSuncoast Neuroscience Associates, Inc., St. Petersburg, Florida, United States
๐บ๐ธRaleigh Neurology Associates, Raleigh, North Carolina, United States
E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT00413192
Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers
- Conditions
- Interventions
- First Posted Date
- 2006-11-23
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT00403520
- Locations
- ๐ซ๐ท
CHU Gui de Chauliac, Montpellier cedex, France
BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 3182
- Registration Number
- NCT00395135
- Locations
- ๐บ๐ธ
Arena Pharmaceuticals, Inc., San Diego, California, United States
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 762
- Registration Number
- NCT00388726
- Locations
- ๐บ๐ธ
Montana Cancer Specialists, Missoula, Montana, United States
๐บ๐ธBellflower Satellite, Bellflower, California, United States
๐บ๐ธWeill Cornell Breast Cancer Center, New York, New York, United States
A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
- Conditions
- Interventions
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT00381173
- Locations
- ๐บ๐ธ
M. D. Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
- First Posted Date
- 2006-09-11
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT00374660